• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4598324)   Today's Articles (2103)   Subscriber (49356)
Number Citation Analysis
76
Hayashi Y. [Economics of medicament therapies for osteoporosis]. NIHON RINSHO. JAPANESE JOURNAL OF CLINICAL MEDICINE 2009;67:1022-1026. [PMID: 19432127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
77
Shidara K, Inaba M. [Bone metabolic marker for osteoporosis]. NIHON RINSHO. JAPANESE JOURNAL OF CLINICAL MEDICINE 2009;67:927-931. [PMID: 19432111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
78
Kishimoto H. [Combination therapy for osteoporosis]. NIHON RINSHO. JAPANESE JOURNAL OF CLINICAL MEDICINE 2009;67:975-979. [PMID: 19432119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
79
Cosman F. Parathyroid hormone treatment for osteoporosis. Curr Opin Endocrinol Diabetes Obes 2008;15:495-501. [PMID: 18971677 DOI: 10.1097/med.0b013e32831a46d6] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
80
Harris HA, Chennathukuzhi VM, Zhang X, Mekonnen B, Jelinsky SA, Schelling SH, Patel VS, Huselton C, Negahban A, Azam F, Winneker RC. Development of an early biomarker for the ovarian liability of selective estrogen receptor modulators in rats. J Steroid Biochem Mol Biol 2008;112:40-6. [PMID: 18824103 DOI: 10.1016/j.jsbmb.2008.08.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/29/2008] [Revised: 07/22/2008] [Accepted: 08/18/2008] [Indexed: 10/21/2022]
81
Ohta H. [Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis]. CLINICAL CALCIUM 2008;18:1442-1450. [PMID: 18830041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
82
Miki T, Masaki H. [Daily practice using the guidelines for prevention and treatment of osteoporosis. Utilization of metabolic markers of bone in daily osteoporosis practice]. CLINICAL CALCIUM 2008;18:1127-1134. [PMID: 18677050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
83
Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C, Deswaef A, Verpooten GA, Reginster JY. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 2008;19:811-8. [PMID: 17999022 DOI: 10.1007/s00198-007-0506-x] [Citation(s) in RCA: 169] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/16/2007] [Accepted: 10/16/2007] [Indexed: 01/06/2023]
84
Abu-Fanne R, Brzezinski A, Golomb M, Grad E, Foldes AJ, Shufaro Y, Varon D, Brill A, Lotan C, Danenberg HD. Effects of estradiol and raloxifene on arterial thrombosis in ovariectomized mice. Menopause 2008;15:98-104. [PMID: 17549036 DOI: 10.1097/gme.0b013e318054e2ab] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
85
Fernández-García D, Muñoz-Torres M, Mezquita-Raya P, de la Higuera M, Alonso G, Reyes-García R, Ochoa AS, Ruiz-Requena ME, Luna JD, Escobar-Jiménez F. Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis. J Endocrinol Invest 2008;31:416-21. [PMID: 18560259 DOI: 10.1007/bf03346385] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
86
Mashiba T. [Assessment of bone quality. Bone quality and osteoporosis treatment]. CLINICAL CALCIUM 2008;18:300-307. [PMID: 18310816] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
87
Majima T, Komatsu Y, Shimatsu A, Satoh N, Fukao A, Ninomiya K, Matsumura T, Nakao K. Efficacy of combined treatment with raloxifene and alfacalcidol on bone density and biochemical markers of bone turnover in postmenopausal osteoporosis. Endocr J 2008;55:127-34. [PMID: 18219181 DOI: 10.1507/endocrj.k07e-027] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]  Open
88
Eiken PA. [Long term effects of raloxifen on the bones]. Ugeskr Laeger 2008;170:224-226. [PMID: 18282451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
89
Rizzoli R. Osteoporosis: non-hormonal treatment. Climacteric 2008;10 Suppl 2:74-8. [PMID: 17882678 DOI: 10.1080/13697130701600815] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
90
Adami S, San Martin J, Muñoz-Torres M, Econs MJ, Xie L, Dalsky GP, McClung M, Felsenberg D, Brown JP, Brandi ML, Sipos A. Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis. Osteoporos Int 2008;19:87-94. [PMID: 17938984 DOI: 10.1007/s00198-007-0485-y] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/09/2007] [Accepted: 05/02/2007] [Indexed: 10/22/2022]
91
Majima T, Komatsu Y, Shimatsu A, Satoh N, Fukao A, Ninomiya K, Matsumura T, Nakao K. Clinical significance of 1-year treatment with raloxifene on bone and lipid metabolism in Japanese postmenopausal women with osteoporosis. Endocr J 2007;54:855-62. [PMID: 17917307 DOI: 10.1507/endocrj.k06-208] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]  Open
92
Okano H. [Evidence of raloxifene on postmenopausal osteoporosis]. NIHON RINSHO. JAPANESE JOURNAL OF CLINICAL MEDICINE 2007;65 Suppl 9:374-380. [PMID: 18161135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
93
Hagino H. [Combination therapy for osteoporosis]. NIHON RINSHO. JAPANESE JOURNAL OF CLINICAL MEDICINE 2007;65 Suppl 9:316-320. [PMID: 18161124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
94
Mizunuma H. [CORE study]. NIHON RINSHO. JAPANESE JOURNAL OF CLINICAL MEDICINE 2007;65 Suppl 9:294-298. [PMID: 18161121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
95
Ringe JD, Christodoulakos GE, Mellström D, Petto H, Nickelsen T, Marín F, Pavo I. Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women. Curr Med Res Opin 2007;23:2677-87. [PMID: 17883882 DOI: 10.1185/03007x226357] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
96
Nakamura T. [Adverse events of drugs for the treatment of osteoporosis]. NIHON RINSHO. JAPANESE JOURNAL OF CLINICAL MEDICINE 2007;65 Suppl 8:304-310. [PMID: 18074553] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
97
Hochberg MC, Rizzoli R. Long-term experience with alendronate in the treatment of osteoporosis. Expert Opin Pharmacother 2007;7:1201-10. [PMID: 16732706 DOI: 10.1517/14656566.7.9.1201] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
98
Zhou GJ, Zhang H, Zhi SD, Jiang GP, Wang J, Zhang M, Gan JX, Xu SW, Jiang GY. Protective effect of raloxifene on lipopolysaccharide and acid- induced acute lung injury in rats. Acta Pharmacol Sin 2007;28:1585-90. [PMID: 17883944 DOI: 10.1111/j.1745-7254.2007.00637.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]  Open
99
Lasco A, Gaudio A, Morini E, Morabito N, Nicita-Mauro C, Catalano A, Denuzzo G, Sansotta C, Xourafa A, Macrì I, Frisina N. Effect of long-term treatment with raloxifene on mammary density in postmenopausal women. Menopause 2007;13:787-92. [PMID: 16912660 DOI: 10.1097/01.gme.0000233493.20712.ad] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
100
Ozmen B, Kirmaz C, Aydin K, Kafesciler SO, Guclu F, Hekimsoy Z. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis. Eur Cytokine Netw 2007;18:148-53. [PMID: 17823083 DOI: 10.1684/ecn.2007.0097] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/16/2007] [Indexed: 11/17/2022]
PrevPage 4 of 12 123451112Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA